123 related articles for article (PubMed ID: 27896231)
1. Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment.
Rosamilio R; Giudice V; Ferrara I; Annunziata S; Pezzullo L; Villani G; Baldi C; Guariglia R; Rocco M; Selleri C
Transl Med UniSa; 2016 Nov; 15():80-83. PubMed ID: 27896231
[TBL] [Abstract][Full Text] [Related]
2. Moderate-dose cyclophosphamide in the treatment of relapsed/refractory T-cell large granular lymphocytic leukemia-associated pure red cell aplasia.
Peng G; Yang W; Zhang L; Zhou K; Li Y; Li Y; Ye L; Li J; Fan H; Song L; Zhao X; Wu Z; Zhang F; Jing L
Hematology; 2016 Apr; 21(3):138-43. PubMed ID: 27077768
[TBL] [Abstract][Full Text] [Related]
3. Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment.
Pelliccia S; Di Napoli A; Naso V; Alma E; Rebecchini C; Cox MC
Eur J Haematol; 2013 Aug; 91(2):183-6. PubMed ID: 23692265
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
5. Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum.
Neff JL; Rangan A; Jevremovic D; Nguyen PL; Chiu A; Go RS; Chen D; Morice WG; Shi M
Hum Pathol; 2018 Nov; 81():96-104. PubMed ID: 29949739
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.
Kath R; Blumenstengel K; Fricke HJ; Höffken K
J Cancer Res Clin Oncol; 2001 Jan; 127(1):48-54. PubMed ID: 11206271
[TBL] [Abstract][Full Text] [Related]
7. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions.
Weide R; Feiten S; Friesenhahn V; Heymanns J; Kleboth K; Thomalla J; van Roye C; Köppler H
Leuk Lymphoma; 2013 Aug; 54(8):1640-6. PubMed ID: 23151046
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
[TBL] [Abstract][Full Text] [Related]
9. T-cell large granular lymphocytic (LGL) leukemia consists of CD4
Kuwahara N; Kodaka T; Zushi Y; Sasaki M; Goka T; Maruoka H; Aoyama Y; Tsunemine H; Yamane T; Kobayashi J; Kawakami T; Ishida F; Itoh T; Takahashi T
J Clin Exp Hematop; 2019; 59(4):202-206. PubMed ID: 31866622
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
Weide R; Heymanns J; Gores A; Köppler H
Leuk Lymphoma; 2002 Feb; 43(2):327-31. PubMed ID: 11999564
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and laboratory analysis of 17 patients with γδT-cell large granular lymphocyte leukemia].
Zhu YM; Gao QY; Hu J; Liu X; Guan DR; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):112-116. PubMed ID: 32135626
[No Abstract] [Full Text] [Related]
12. [The clinical and laboratory characteristics of T cell large granular lymphocyte leukemia].
Zhao X; Zhou K; Wang HJ; Zhang L; Liu QG; Jing LP; Li HQ; Yang DL; Chu YL; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2009 Mar; 30(3):179-82. PubMed ID: 19642367
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine salvage therapy for T cell neoplasms.
Zaja F; Baldini L; Ferreri AJ; Luminari S; Grossi A; Salvi F; Zambello R; Goldaniga M; Volpetti S; Fanin R
Ann Hematol; 2013 Sep; 92(9):1249-54. PubMed ID: 23592272
[TBL] [Abstract][Full Text] [Related]
14. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
Reboursiere E; Le Bras F; Herbaux C; Gyan E; Clavert A; Morschhauser F; Malak S; Sibon D; Broussais F; Braun T; Fornecker LM; Garidi R; Tricot S; Houot R; Joly B; Abarah W; Choufi B; Pham AD; Gac AC; Fruchart C; Marin E; Safar V; Parcelier A; Maisonneuve H; Bachy E; Cartron G; Jaccard A; Tournilhac O; Rossi C; Schirmer L; Martignoles JA; Gaulard P; Tilly H; Damaj G;
Oncotarget; 2016 Dec; 7(51):85573-85583. PubMed ID: 27458168
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience.
Zhu Y; Gao Q; Hu J; Liu X; Guan D; Zhang F
Leuk Res; 2020 Mar; 90():106299. PubMed ID: 32035354
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Large Granular Lymphocyte Leukemia (LGLL)-A Case Series of Challenging Presentations.
Pflug N; Littauer A; Beverungen D; Sretenovic A; Wahnschaffe L; Braun T; Dechow A; Jungherz D; Otte M; Monecke A; Bach E; Franke GN; Schwind S; Jentzsch M; Platzbecker U; Herling M; Vucinic V
Front Oncol; 2021; 11():775313. PubMed ID: 35070980
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes.
Olson KC; Kulling Larkin PM; Signorelli R; Hamele CE; Olson TL; Conaway MR; Feith DJ; Loughran TP
Cytokine; 2018 Nov; 111():551-562. PubMed ID: 30455079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
